by Hormone replacement therapy can increase the risk of breast cancer in some younger women, according to a Lancet study.
An international team of researchers found that the treatment as a whole was not associated with young breast cancer.
However, estrogen plus progestin therapy seems to increase the risk of breast cancer by 10 percent.
In the meantime, the application of estrogen hormone therapy seemed to reduce the risk of breast cancer by 14 percent.
Hormone replacement therapy is a treatment with which the symptoms of menopause help.
There are different types of HRT used to treat symptoms of menopause.
They contain different hormones: some are estrogen products; Others contain testogenic and other types have both.
These drugs can be taken or used in different ways and work by replacing the estrogen and progesterone of the hormones, which can fall on lower values when women approach menopause.
In older women, most of the studies that examine the connections between hormone therapy and breast cancer risk.
Previous work that has concentrated on women who have already passed the menopause suggest that estrogen and progestin hormone therapy is a risk factor for breast cancer.
Therapy after the operation
The researchers, led by academics of the National Institute for Environmental Health Sciences in the United States, wanted to examine the risks of younger women for hormone therapy – which can take these drugs according to gynecological operation or during perimenopause.
The new meta -analysis published in the magazine Lancet Oncology examined data from previous studies with 459,476 women aged 16 to 54.
About two percent of this group (8,455) developed young breast cancer, which means that the disease was diagnosed before they were 55 years old.
And 15 percent of the women involved in the study reported on hormone therapy, with estrogen plus progestin hormone therapy and estrogen being the most common types.
“Although the strength of these associations could vary after age in the first application, the duration of the application, the status of gynecological surgery and other factors, the use of estrogen hormone therapy without the presence seems to reduce breast cancer risk and estrogen as well as the progestin therapy of breast cancer,” wrote the authors.
“The results can be used to increase the clinical recommendations for the use of hormone therapy in young women, for whom the instructions were previously scarce.”
Dr. Kotryna Temcinait, the head of research communication in breast cancer, said: “These results largely match what we already know about taking HRT for menopause and its effects on breast cancer risk – for most people, the risk of developing breast cancer is small and is predominated by the advantages.
“Taking HRT is a very personal decision. It is therefore important that everyone has the information about the advantages and risks, which is discussed and supported with their family doctor or specialist team to make the choice that is correct for them.”
